PERFORM Publications

Keyword search (4,163 papers available)

Title		Authors	PubMed ID
1	Resources and Methods for Engineering "Designer" Glycan-Binding Proteins.	Warkentin R, Kwan DH	33450899 CHEMBIOCHEM
2	Cyst Reduction by Melatonin in a Novel Drosophila Model of Polycystic Kidney Disease.	Millet-Boureima C; Rozencwaig R; Polyak F; Gamberi C;	33238462 BIOLOGY
3	Gold Nano-Island Platforms for Localized Surface Plasmon Resonance Sensing: A Short Review.	Badilescu S, Raju D, Bathini S, Packirisamy M	33066088 ENCS
4	Angiotensin-I-Converting Enzyme Inhibitory Activity of Coumarins from Angelica decursiva.	Ali MY, Seong SH, Jung HA, Choi JS	31683604 CHEMBIOCHEM
5	Pyrrole and Fused Pyrrole Compounds with Bioactivity against Inflammatory Mediators.	Said Fatahala S, Hasabelnaby S, Goudah A, Mahmoud GI, Helmy Abd-El Hameed R	28304349 CHEMBIOCHEM
6	Altering Residue 134 Confers an Increased Substrate Range of Alkylated Nucleosides to the E. coli OGT Protein.	Schoonhoven NM, O'Flaherty DK, McManus FP, Sacre L, Noronha AM, Kornblatt MJ, Wilds CJ	29137116 CHEMBIOCHEM

Title:	Cyst Reduction by Melatonin in a Novel Drosophila Model of Polycystic Kidney Disease.
Authors:	Millet-Boureima C, Rozencwaig R, Polyak F, Gamberi C
Link:	https://www.ncbi.nlm.nih.gov/pubmed/33238462
DOI:	10.3390/molecules25225477
Publication:	Molecules (Basel, Switzerland)
Keywords:	Drosophila; longevity; melatonin; oxidative stress; polycystic kidney disease; renal cysts;
PMID:	33238462	Category:	Molecules	Date Added:	2020-11-27
Dept Affiliation:	BIOLOGY 1 Biology Department, Concordia University, Montreal, QC H4B 1R6, Canada. 2 BH Bioscience, Montreal, QC H3W 2L2, Canada.

Description:

Cyst Reduction by Melatonin in a Novel Drosophila Model of Polycystic Kidney Disease.

Molecules. 2020 Nov 23; 25(22):

Authors: Millet-Boureima C, Rozencwaig R, Polyak F, Gamberi C

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) causes progressive cystic degeneration of the renal tubules, the nephrons, eventually severely compromising kidney function. ADPKD is incurable, with half of the patients eventually needing renal replacement. Treatments for ADPKD patients are limited and new effective therapeutics are needed. Melatonin, a central metabolic regulator conserved across all life kingdoms, exhibits oncostatic and oncoprotective activity and no detected toxicity. Here, we used the Bicaudal C (BicC) Drosophila model of polycystic kidney disease to test the cyst-reducing potential of melatonin. Significant cyst reduction was found in the renal (Malpighian) tubules upon melatonin administration and suggest mechanistic sophistication. Similar to vertebrate PKD, the BicC fly PKD model responds to the antiproliferative drugs rapamycin and mimics of the second mitochondria-derived activator of caspases (Smac). Melatonin appears to be a new cyst-reducing molecule with attractive properties as a potential candidate for PKD treatment.

PMID: 33238462 [PubMed - in process]

BookR: School of Health Core Facilities Booking

"Molecules" Category Publications:

Search Publications

No results